%0 Journal Article
%T Calcitonin-Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention; Literature Review
%A Haneen Ahmed Khouja
%A Rawan Awadh Alshehri
%A Hussain Mirza Alhalal
%A Hassan Dhafer Alabisi
%A Salhah Mohammad Alajmi
%A Zahra Moneer Al Radi
%A Zainab Abduljabbar Al Hamoud
%A Asma Wadi Zaid Alshammari
%A Danah Youssef A Albouri
%A Abrar Talat Saeed Aleysawi
%A Raghad Khalid Alammari
%J World Journal of Environmental Biosciences
%@ 2277-8047
%D 2021
%V 10
%N 1
%R 10.51847/ogC7ozOJpH
%P 48-51
%X Migraine is one of the most common disabling disorders worldwide that influence the patient functionality and quality of life. Current preventive therapy has succeeded in preventing and decreasing migraine days; however, unwanted adverse effects are considered a serious issue and can lead to discontinuation of the medication. The calcitonin-gene-related peptide is a neuropeptide that plays a major role in migraine pathogenesis, and inhibiting this peptide is thought to achieve a therapeutic role in migraine prevention.  This literature review aims to review the role of this peptide in migraine pathogenesis and the implementation of monoclonal antibodies in migraine preventive therapy.  A relevant articles were collected from the PubMed database, using the following Mesh words: Calcitonin-gene-related peptide, migraine, migraine prevention. Calcitonin-gene-related peptide monoclonal antibodies seem to have a significant therapeutic role in migraine prevention. Few side effects were reported, of which infection was the common reported one. The long-term safety profile has not been evaluated up to our knowledge. Therefore, a long-term safety assessment would be required in addition to comparison with the standard migraine preventive therapy.
%U https://environmentaljournals.org/article/calcitonin-gene-related-peptide-cgrp-monoclonal-antibodies-in-migraine-prevention-literature-revi-hrc6bgjul6jwbbw